506208866 08/18/2020

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1 Stylesheet Version v1.2 EPAS ID: PAT6255606

SUBMISSION TYPE:	NEW ASSIGNMENT
NATURE OF CONVEYANCE:	ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
HEATHER COATE	08/04/2020
CURT A DVORAK	08/04/2020

RECEIVING PARTY DATA

Name:	JANSSEN PHARMACEUTICA NV
Street Address:	TURNHOUTSEWEG 30
City:	BEERSE
State/Country:	BELGIUM
Postal Code:	B-2340

PROPERTY NUMBERS Total: 1

Property Type	Number
Application Number:	16899847

CORRESPONDENCE DATA

Fax Number: (617)902-2621

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.

Phone: 6172946604

Email: docketing@biospark-ip.com

Correspondent Name: BIOSPARK INTELLECTUAL PROPERTY LAW

Address Line 1: 1 BROADWAY
Address Line 2: 14TH FLOOR

Address Line 4: CAMBRIDGE, MASSACHUSETTS 02142

ATTORNEY DOCKET NUMBER:	JNJ-012US
NAME OF SUBMITTER:	RAQUEL AIDUN
SIGNATURE:	/Raquel Aidun/
DATE SIGNED:	08/18/2020

Total Attachments: 6

source=200818_JNJ-012US_Assignment#page1.tif source=200818_JNJ-012US_Assignment#page2.tif source=200818_JNJ-012US_Assignment#page3.tif source=200818_JNJ-012US_Assignment#page4.tif

PATENT 506208866 REEL: 053525 FRAME: 0441

source=200818_JNJ-012US_Assignment#page5.tif source=200818_JNJ-012US_Assignment#page6.tif

PATENT REEL: 053525 FRAME: 0442

COMBINED DECLARATION AND ASSIGNMENT		
Title of Invention: SUBSTITUTED PYRAZOI	LO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS	
This declaration and assignment is directed to:	The attached or filed herewith application of (list of named inventors),	
or		
	The United States application or PCT international application number <u>16/899,847</u> filed on <u>June 12, 2020</u> .	
Declaration		
As the below named inventor, I hereby deci	lare that:	
The above-identified application ("Applica	tion") was made or authorized by me.	
I believe that I am the original inventor or a	nn original inventor of a claimed invention or discovery in the Application.	
	nts of the Application, including the claims, and I acknowledge the duty to disclose fined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of	
	e statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or h for filings of this Application in the United States of America.	
Assignment	Janssen Pharmaceutica NV Turnhoutseweg 30 B-2340 Beerse, Belgium	
	oration of the state or country of Belgium einafter designated as the "Assignee"),	
	the above-identified invention by previous assignment (attached hereto) to Assignee Patent Office and I confirm I have and do assign and transfer:	
or		
For good and valuable consideration, the assigned and transferred to Assignee, such assignment	sufficiency of which is acknowledged, I hereby assign and transfer and/or have ant being made effective as of June 14, 2019:	
the right to claim priority to the Application, all inv States, European Patent Office and of all other consuch inventions or discoveries and all rights in continuations thereof, and to all Letters Patent that supplementary protection certificates, reexamination	the Application, including all priority rights for other countries arising therefrom and ventions or discoveries therein disclosed, and any and all Letters Patent of the United antries, which may be granted for such inventions or discoveries, or any of them, all such Application including any and all provisionals, substitutions, divisions, and t may be granted for said inventions and discoveries, and in and to all extensions, as, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use for which such Letters Patent may be granted, as fully and entirely as the same would sent and sale not been made.	
Office, any other patent offices, and under the Pater any reexamination of any of such applications, ar	th the Application in the United States Patent and Trademark Office, European Patent at Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, and any patent term extensions or supplementary protection certificates of any such ents in connection with such applications as the Assignee may deem necessary or	

1

expedient.

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

Heather COATE Heather Coate Signature Heather Coate (Aug 4, 2020 08:24 PDT) Date Aug 4, 2020 Date

LEGAL NAME OF INVENTOR

PATENT

JAB7025USNP1_DEC-ASSIGNMENT_COATE

Final Audit Report 2020-08-04

Created: 2020-08-04

By: Gayle Gestick (ggestick@ITS.JNJ.com)

Status: Signed

Transaction ID: CBJCHBCAABAAFPrTiT9_UzoHU1nyo79RcccS9k87lh_7

"JAB7025USNP1_DEC-ASSIGNMENT_COATE" History

- Document created by Gayle Gestick (ggestick@ITS.JNJ.com) 2020-08-04 0:10:09 AM GMT- IP address: 70.137.105.184
- Document emailed to Heather Coate (hcoate@its.jnj.com) for signature 2020-08-04 0:10:48 AM GMT
- Email viewed by Heather Coate (hcoate@its.jnj.com) 2020-08-04 0:18:38 AM GMT- IP address: 71.128.9.43
- Document e-signed by Heather Coate (hcoate@its.jnj.com)

 Signature Date: 2020-08-04 3:24:47 PM GMT Time Source: server- IP address: 148.177.96.201
- Signed document emailed to Heather Coate (hcoate@its.jnj.com) and Gayle Gestick (ggestick@ITS.JNJ.com) 2020-08-04 3:24:47 PM GMT

Johnson-Johnson

Adobe Sign

COMBINED DECLARATION AND ASSIGNMENT

Title of Invention: SUBSTITUT	ED PYRAZOI	LO-PYRAZINES AND THEIR USE AS GLUN2B RECEPTOR MODULATORS
This declaration and assignment is dir	rected to:	The attached or filed herewith application of (list of named inventors),
	or	
	\boxtimes	The United States application or PCT international application number 16/899,847 filed on June 12, 2020.
Declaration		
As the below named invento	r, I hereby dec	lare that:
The above-identified applica	tion ("Applica	tion") was made or authorized by me.
I believe that I am the original	al inventor or a	an original inventor of a claimed invention or discovery in the Application.
	ntability as de	nts of the Application, including the claims, and I acknowledge the duty to disclose fined in Title 37, the United States Code of Federal Regulations, §1.56 for filings of
I hereby acknowledge that any willful false statement made in this declaration is punishable under 18 U.S.C. § 1001 by fine or imprisonment of not more than five (5) years, or both for filings of this Application in the United States of America.		
Assignment		Janssen Pharmaceutica NV Turnhoutseweg 30 B-2340 Beerse, Belgium
		oration of the state or country of Belgium einafter designated as the "Assignee"),
		the above-identified invention by previous assignment (attached hereto) to Assignee S Patent Office and I confirm I have and do assign and transfer:
or		
		sufficiency of which is acknowledged, I hereby assign and transfer and/or have ant being made effective as of June 14, 2019:
the right to claim priority to the Appl States, European Patent Office and osuch inventions or discoveries and continuations thereof, and to all Let supplementary protection certificates,	lication, all involuding the course all rights in ters Patent that reexamination erm or terms f	the Application, including all priority rights for other countries arising therefrom and rentions or discoveries therein disclosed, and any and all Letters Patent of the United antries, which may be granted for such inventions or discoveries, or any of them, all such Application including any and all provisionals, substitutions, divisions, and t may be granted for said inventions and discoveries, and in and to all extensions, as, renewals, and reissues thereof, to be held and enjoyed by Assignee for its own use for which such Letters Patent may be granted, as fully and entirely as the same would tent and sale not been made.
I shall execute all papers necessary in connection with the Application in the United States Patent and Trademark Office, European Patent Office, any other patent offices, and under the Patent Cooperation Treaty, and any continuing, divisional, or reissue applications thereof, any reexamination of any of such applications, and any patent term extensions or supplementary protection certificates of any such applications and also to execute separate assignments in connection with such applications as the Assignee may deem necessary or expedient.		

1

PATENT

I shall execute all papers necessary in connection with any litigation or any other judicial proceeding in the United States or other country, or any administrative proceeding in the United States Patent and Trademark Office, European Patent Office, any other patent office, or under the Patent Cooperation Treaty concerning the Application(s) or any continuation, divisional, or reissue applications thereof, or any reexamination of any such applications, or any Letters Patent issued therefrom or any patent term extensions or supplementary protection certificates of any such applications and to cooperate with the Assignee in every way possible in obtaining evidence and going forward with such litigation or proceeding.

I shall execute all papers and documents and perform any act which may be necessary in connection with claims or provisions of the International Convention for Protection of Industrial Property or similar agreements.

I shall do all other acts which, in the opinion of Assignee, may be necessary or desirable to secure the grant of Letters Patent to Assignee or its nominees, in the United States, by the European Patent Office and in all other countries where Assignee may desire to have such inventions or discoveries, or any of them, patented, with specifications and claims in such form as shall be approved by Assignee and to vest and confirm in Assignee or its nominees the full and complete legal and equitable title to all such Letters Patent.

I hereby (i) authorize and request the Commissioner of Patents to issue any and all Letters Patent of the United States resulting from the Application or any divisional, continuation, or reissue applications thereof, and any reexamination of any of such applications, to Assignee, and (ii) covenant that I have full right to convey the interest herein assigned, and that I have not executed, and will not execute, any agreement in conflict herewith.

I hereby grant the attorney of record the power to insert on this assignment any further identification which may be necessary or desirable in order to obtain legal recordation of this document.

Curt DVORAK	
Curt A Dvorak Curt A Dvorak (Aug 4, 2020 03:27 PDT)	Aug 4, 2020
Signature	Date

LEGAL NAME OF INVENTOR

JAB7025USNP1_DEC-ASSIGNMENT_DVORA

Final Audit Report 2020-08-04

Created: 2020-08-04

Gayle Gestick (ggestick@ITS.JNJ.com) Ву:

Signed Status:

CBJCHBCAABAARKTIAIIVI3yb9BwFdhm8dJgVVUmdY-lc Transaction ID:

"JAB7025USNP1_DEC-ASSIGNMENT_DVORAK" History

- Document created by Gayle Gestick (ggestick@ITS.JNJ.com) 2020-08-04 - 0:11:14 AM GMT- IP address: 70.137.105.184
- Document emailed to Curt A Dvorak (cdvorak@its.jnj.com) for signature 2020-08-04 - 0:11:44 AM GMT
- Email viewed by Curt A Dvorak (cdvorak@its.jnj.com) 2020-08-04 - 3:27:45 PM GMT- IP address: 70.179.11.157
- Document e-signed by Curt A Dvorak (cdvorak@its.jnj.com) Signature Date: 2020-08-04 - 3:27:59 PM GMT - Time Source: server- IP address: 70.179.11.157
- Signed document emailed to Gayle Gestick (ggestick@ITS.JNJ.com) and Curt A Dvorak (cdvorak@its.jnj.com) 2020-08-04 - 3:27:59 PM GMT

Johnson-Johnson

Adobe Sign

RECORDED: 08/18/2020